Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adalimumab Versus Ustekinumab in Management of Inflammatory Bowel Disease in Egyptian Patients

NCT05720221 is registered in ClinicalTrials.gov with Helwan University as lead sponsor.

NCT NCT05720221
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05720221 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adalimumab Versus Ustekinumab in Management of Inflammatory Bowel Disease in Egyptian Patients
Lead sponsor
Helwan University
Phase
Observational
Overall status
Completed
Start date
July 15, 2021
Completion date
January 20, 2023
Enrollment
100 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ibd